*:Co-first author; #:Co-corresponding author
1.Wang H*, Chen Y*, Yang Y, Song R, Gu S, Cao X, Zhang L, Yang Y, Hou T, Qi X, Yang Y, Wang Y, Bai T, Feng D, Yang X#, He J#. MAGI3 enhances sensitivity to sunitinib in renal cell carcinoma by suppressing the MAS/ERK axis and serves as a prognostic marker. Cell Death Dis. 2025;16(1):102.
2.Wang H*, Zhang L*, Liu H, Yang Y, Lu W, Cao X, Yang X, Qin Q, Song R, Feng D, Wang S, Bai T#, He J#. PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway. Br J Cancer. 2024;131(2):347-360.
3.Wang H, Yang W, Qin Q, Yang X, Yang Y, Liu H, Lu W, Gu S, Cao X, Feng D, Zhang Z#, He J#. E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer. Mol Cancer. 2022; 21(1):151.
4.Yang Y*, Liang J*, Zhao C, Chen Y, Gu S, Yang X, Liu H, Qin Q, Wang H, Yang Z, Cao X, Feng D, He J. NHERF4 hijacks Mas-mediated PLC/AKT signaling to suppress the invasive potential of clear cell renal cell carcinoma cells. Cancer Lett. 2021; 519:130-140.
5.Zhao C*, Tao T*, Yang L*, Qin Q#, Wang Y, Liu H, Song R, Yang X, Wang Q, Gu S, Xiong Y, Zhao D, Wang S, Feng D, Jiang WG, Zhang J#, He J#. Loss of PDZK1 expression activates PI3K/AKT signaling via PTEN phosphorylation in gastric cancer. Cancer Lett. 2019; 453:107-121.
6.Wang Q*, Song R*, Zhao C, Liu H, Yang Y, Gu S, Feng D, He J. HPV16 E6 promotes cervical cancer cell migration and invasion by downregulation of NHERF1. Int J Cancer. 2019;144(7):1619-1632.
7.Wang Q*, Qin Q*, Song R*, Zhao C, Liu H, Yang Y, Gu S, Zhou D, He J. NHERF1 inhibits beta-catenin-mediated proliferation of cervical cancer cells through suppression of alpha-actinin-4 expression. Cell Death Dis. 2018; 9(6):668.
8.Tao T*, Yang X*, Zheng J, Feng D, Qin Q, Shi X, Wang Q, Zhao C, Peng Z, Liu H#, Jiang WG, He J#. PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation. Oncogene. 2017; 36(44):6119-6131.
9.He J, Wang H. Application of MAGI3 in predicting prognosis or chemotherapy sensitivity of colorectal cancer patients. Chinese patent ZL202011456573.7.
10.He J, Zheng J, Peng Z, Liu H, Tao T. PDZK1 as a biomarker for renal cell carcinoma and its applications. Chinese patent ZL201610420029.4.